chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Throat closing; Joint pain in shoulder; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 01-Mar-2021 and was forwarded to Moderna on 01-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of THROAT TIGHTNESS (Throat closing) and ARTHRALGIA (Joint pain in shoulder) in a 79-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Multiple myeloma.    On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Feb-2021, the patient experienced THROAT TIGHTNESS (Throat closing) and ARTHRALGIA (Joint pain in shoulder). On 24-Feb-2021, THROAT TIGHTNESS (Throat closing) had resolved. On 27-Feb-2021, ARTHRALGIA (Joint pain in shoulder) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
This spontaneous report as received from a pharmacist refers to a female patient of unknown age. The patient's relevant medical history, and past drug history were unknown. On 20-SEP-2013 the patient was vaccinated with one dose of ZOSTAVAX (lot number reported as J003799, expiration date 28-JUN-2014) (strength and dose were not reported). Concomitant medications were not reported. On 21-SEP-2013, the patient experienced  nasal Staphylococcal infection and was prescribed with CIPRO at an unknown dose. It was unknown if there was any relevant laboratory data. Patient continued experiencing the nasal Staphylococcal infection. The relationship between ZOSTAVAX and the Staphylococcal infection was not reported. Additional information has been requested.
Patient experienced syncope; dose of HPV vaccine; This spontaneous report was received from a consumer through Pfizer, referring to a 16-year-old female patient. Information regarding the patient's medical history, concurrent conditions and concomitant therapies was not provided.   On an unspecified date, the patient was administered a dose of HPV rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) or quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) (reported as HPV vaccine, manufacturer unknown) (product origin unknown) as prophylaxis (dose, route of administration, vaccine scheme, lot number and expiration date were not reported). Other suspect vaccine included meningococcal vaccine b rfhbpa/fhbpb (TRUMENBA) (indication, dose, route of administration, lot number and expiration date were not reported).   After the administration of the vaccines, the patient experienced syncope. The outcome of syncope and the causal relationship between the suspect vaccines and the event were not reported.   Upon internal review, the event of syncope was determined to be medically significant.
no additional AEs; MMR II that underwent multiple temperature excursions were administered; This spontaneous report was received from a physician referring to a patient of unknown age and gender. The patient's concomitant medication, pertinent medical history and drug allergies or reactions were not reported.   On 29-MAR-2021, the patient was vaccinated with improperly stored measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) recombinant Human albumin (rHA)(strength, dose and route were not reported, lot # S020162, expiration date: 30-JUN-2021) for prophylaxis (product storage error).         It was reported that the suspect vaccine was exposed to temperatures of minus 58 Fahrenheit (F) to 46 F for a 1 hour 53 minutes 0 seconds; 56.3 F for 0 hours 48 minutes 0 seconds; 47.8 F for 0 hours 11 minutes 0 seconds; 47.8 F 0 hours 5 minutes 0 seconds, as recorded by the digital data logger. Previous excursions included 57 F for 1 hour 53 minutes 0 seconds; 56.3 F for 0 hours 48 minutes 0 seconds; 47.8 F for 0 hours 11 minutes 0 seconds. No additional adverse event (AE) information was provided.   This is one of the multiple reports reported by the same reporter.; Sender's Comments:  US-009507513-2106USA007355:
Information has been received from the step-mother of a 21 year old female and through a Merck Pregnancy Registry.  The 21 year old female had no pertinent medical history and no drug reactions or allergies who on approximately 16-APR-2007, "approximately 2 weeks ago" was vaccinated "in the hip area" with the first dose of GARDASIL.  The lot number was not available.  There was no concomitant medication.  It was reported that the patient discovered that she was pregnant approximately a week and a half later on 27-APR-2007.  The patient had not visited her physician regarding the pregnancy as of today.  It was reported that the patient was approximately 6 weeks pregnant.  In follow-up it was reported by a nurse practitioner, who was a nurse midwife concerning a 21 year old, female, patient, with the last menstrual period was 16-MAR-2007, who on 20-APR-2007 received her first dose of GARDASIL, (Lot # 657006/0188U).  It was reported that the patient was pregnant with an estimated date of delivery of 21-Dec-2007.  It was reported that the patient sought unspecified medical attention.  Laboratory evaluation revealed a positive serum pregnancy test and the patient had a fetal ultrasound (results not reported).  Follow-up information indicated that on 12-DEC-2007 the patient gave birth to an infant that weighed 7 pounds 12 ounces.  The infant was healthy and normal.  It was reported that the mother experienced "mild pre-eclampsia and blood pressure issues."  Additional information has been requested.
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose12/18/21 2nd dose01/05/21 Diagnosed covid positive:09/06/21 Symptom onset:09/06/21 Exposure:TRAVEL Symptoms:FEVER, COUGH, MUSCLE ACHES, LOSS OF SMELL/TASTE
This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (felt sick described as felt like had flu), INFLUENZA, RHINORRHOEA (common cold symptom, described as sniffles), PYREXIA (fever) and INJECTION SITE PAIN (extremely sore arm at injection site) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. The patient's past medical history included COVID-19 in February 2021. On 15-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Feb-2021, the patient experienced MALAISE (felt sick described as felt like had flu), INFLUENZA (felt sick described as felt like had flu), RHINORRHOEA (common cold symptom, described as sniffles), PYREXIA (fever), INJECTION SITE PAIN (extremely sore arm at injection site) and MYALGIA (body aches). The patient was treated with ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) at an unspecified dose and frequency. On 18-Feb-2021, MALAISE (felt sick described as felt like had flu), INFLUENZA (felt sick described as felt like had flu), RHINORRHOEA (common cold symptom, described as sniffles), PYREXIA (fever), INJECTION SITE PAIN (extremely sore arm at injection site) and MYALGIA (body aches) had resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown. No concomitant medication was not reported. This case was linked to US-MODERNATX, INC.-MOD-2021-042525 (E2B Linked Report).; Sender's Comments: US-MODERNATX, INC.-MOD-2021-042525:Same reporter (MOD21-052309).
Myocarditis, pericarditis with low normal LV ejection fraction (54%), one 4 beat run of ventricular tachycardia, chest pain.  Also increased troponin levels starting 8/30/2021 in ER, continued to be elevated in hospital, started improving prior to discharge (9/1/2021).  Chest pain only on 8/30/2021.
About 3 days after getting the first shot,  became very ill with nausea, vomiting, diarrhea, muscle weakness and fatigue. Also, lack of appetite. His symptoms lasted about 4 to 5 days.
Patient was given a pediatric dose instead of an adult dose. Patient was given a new apt for 07/27/18 to administer correct adult dose, patient is aware of situation and agreed to come in clinic. Pt did not state to have any abnormal symptoms.
This non-serious medically confirmed report (initial receipt 13-OCT-2014) concerns a 61 year old female patient. ON the 10-OCT-2014, the patient received AFLURIA (batch number: T57005) 0.5 ml annually via the intramuscular route. As the pharmacist was preparing and administering the AFLUIRA injection, while pressing the plunger of the vaccine's syringe, the solution leaked from the syringe and went down the patient's arm. The pharmacist checked the syringe and was positive that everything was tightly screwed in. The syringe appeared different from other syringe, the pharmacist was not sure if the patient received the correct dose. The patient was fine and would return to the pharmacy for re-vaccination. Outcome was unknown.
Pt received shots that morning, developed generalized hives that afternoon.  Was treated with Benadryl orally for 2 days with complete resolution of hives.
swelling in her face, earlobe, temple all the way to her head, and had a nodule on the back of her neck, all on the right side; swelling in her face, earlobe, temple all the way to her head, and had a nodule on the back of her neck, all on the right side; swelling in her face, earlobe, temple all the way to her head, and had a nodule on the back of her neck, all on the right side; scalp was tender to the touch; diagnosed with parotitis; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING FACE (swelling in her face, earlobe, temple all the way to her head, and had a nodule on the back of her neck, all on the right side), EAR SWELLING (swelling in her face, earlobe, temple all the way to her head, and had a nodule on the back of her neck, all on the right side), NODULE (swelling in her face, earlobe, temple all the way to her head, and had a nodule on the back of her neck, all on the right side), PAIN OF SKIN (scalp was tender to the touch) and PAROTITIS (diagnosed with parotitis) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In March 2021, the patient experienced SWELLING FACE (swelling in her face, earlobe, temple all the way to her head, and had a nodule on the back of her neck, all on the right side), EAR SWELLING (swelling in her face, earlobe, temple all the way to her head, and had a nodule on the back of her neck, all on the right side), NODULE (swelling in her face, earlobe, temple all the way to her head, and had a nodule on the back of her neck, all on the right side), PAIN OF SKIN (scalp was tender to the touch) and PAROTITIS (diagnosed with parotitis). At the time of the report, SWELLING FACE (swelling in her face, earlobe, temple all the way to her head, and had a nodule on the back of her neck, all on the right side), EAR SWELLING (swelling in her face, earlobe, temple all the way to her head, and had a nodule on the back of her neck, all on the right side), NODULE (swelling in her face, earlobe, temple all the way to her head, and had a nodule on the back of her neck, all on the right side), PAIN OF SKIN (scalp was tender to the touch) and PAROTITIS (diagnosed with parotitis) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medication was reported.  Treatment information was not provided.
Bad Chills.  On Friday, 2/12, in the a.m., I had bad diarrhea, not sure what caused it.
Asthma; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program (005570). The reporter is the patient.  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administration date Apr2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose: 1), for COVID-19 immunization. The following information was reported: ASTHMA (non-serious) with onset Apr2021, outcome "unknown", described as "Asthma". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: Since receiving the 2nd Pfizer vaccine in Apr2021, the patient had been diagnosed with Asthma. The patient never had it it before. Never have had lung breathing issues. Not sure what to do about this. The patient had chest x-rays, ekg, blood tests and not impacting the heart. The patient need someone to contact to discuss further.  This follow-up is being submitted to notify that the lot/batch number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information is expected.
Back pain; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (Back pain) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BACK PAIN (Back pain). At the time of the report, BACK PAIN (Back pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant product use was reported No treatment information was provided   Reporter did not allow further contact
Rash on face and neck, afebrile. Tylenol prn x2 since vaccine administration. Slept from noon until 3:00 PM.
Sudden onset of hearing loss in both ears (left side more severe), distorted hearing,  everything sounded muffled, unable to understand what teachers and classmates were saying, also had tinnitus, lasted for 48 hours.
client received immz at 10:20 am in office Denied any trouble proceeded to check out and fainted in lobby and obtain laceration to r forehead and under r eye.  BP 106/74 p 64 r 20 at 10:30 recheck at 10:45 106/68 P 62 r 20. After applying pressure to laceration and bleeding stop transported to er by mother for further evaulation of lacerations.
Second dose April 1st Left arm of injection site felt sore next day April 2nd about 5:10Am couldn?t lift left arm had a ball in my armpit, in my neck also had a ball felt hot, body aches along with headache. Eventually side effects disappear but ball in neck was still present
Chills, body aches beginning at around 3:30 AM Sunday 2/28. Felt like low fever but I don?t have a thermometer. Fatigue all day Sunday with aches and chills, no appetite. I took Tylenol every 6 hours.  Then around 1:00 AM Monday 3/1 I began vomiting every half hour or so until 3:30 AM. Feeling fatigue and nausea still at this time.
extreme hard red lump; itchy; This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION SITE ERYTHEMA (extreme hard red lump) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     The patient's past medical history included Stent placement (Cardiac stent).    On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (extreme hard red lump). At the time of the report, VACCINATION SITE ERYTHEMA (extreme hard red lump) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medication include Zyrtec. Concomitant product use was not provided by the reporter.
Patient was monitored and reported dizziness 10 minutes after receiving vaccine, vitals were within normal limits at that time.  After 30 minutes without any other event, patient said she was feeling well and began to leave to go home.  About 3 minutes thereafter reported not feeling well.  She was taken to an exam room, where she lost consciousness and had a seizure for about 2 minutes, vitals remained normal.  Ambulance was called and patient taken to the hospital.
vascular visibility in hands with pain / numbness; vascular visibility in hands with pain / numbness; can see red veins and bruising around it; vascular visibility/ can see red veins; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 619266) via an unspecified route of administration in the left arm on 26Feb2021 at 10:30(at the age of 29-years-old) as a single dose for COVID-19 immunisation. The medical history included seizure disorder. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The concomitant medications included levetiracetam (KEPPRA) and lacosamide (VIMPAT); both for an unknown indication from unknown dates and unknown if ongoing. The patient previously took lamotrigine (MANUFACTURER UNKNOWN) and experienced drug allergy. On 27Feb2021, the patient experienced vascular visibility in hands with pain/numbness and he could see red veins and bruising around it. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events vascular visibility in hands with pain/numbness and could see red veins and bruising around it was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
pt recv vax 22OCT96 & 4DEC96 pt started having SOB & a productive cough;2wk later pt devel chills & fever;pt saw MD 3x;
Patient had worsening of lower extremity edema 4-5 days after his vaccine administration.
pt devel chicken pox in oct95 p/ 6yr old sibling was vaccinated; a second sibling also devel chicken pox;
This case was reported by a pharmacist via call center representative and described the occurrence of feeling unwell in a adult patient who received Shingrix for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, less than a year after receiving Shingrix, the patient experienced feeling unwell. On an unknown date, the outcome of the feeling unwell was unknown. It was unknown if the reporter considered the feeling unwell to be related to Shingrix. Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected as adult as per vaccine indication. The reporter stated that, another pharmacist told her that, the patient experienced not feeling good after Shingrix and even worse after the second dose. The reporter did not had additional details about this report, as she mentioned she heard from another pharmacist. For tolerance to next dose, refer case US2018GSK186788. This case has been linked with the case US2018183672, reported by same reporter.
Patient notes weakness, diarrhea for 2 days, urinary incontinence, lightheadedness, confusion. Noted in Emergency services to be in Afib with RVR, rates in the 140s. Patient was hospitalized and COVID-19 test was positive 11/10/2021. Patient remains hospitalized at time of VAERS report submission
Redness that started as the size of a penny on Tuesday night. Has grown to almost cover my left deltoid. No itching, fever and not warm to the touch. Is painful on palpating.
After receiving the injection, patient become disoriented. After waiting in the parking lot for 15 minutes, patient developed a few hives, was dizzy, chest was tight, and patient had overall discomfort. Patient went back into the facility and reported to staff and was given Benadryl, which slowly started to help. Patient eventually was able to leave, but symptoms, although got better with the benadryl, was uncomfortable for a while, and chest was tight, with dizziness. Hives went away after ingesting medication.
Client reported feeling dizzy about 5 minutes after receiving her second Pfizer dose.  She was found to have elevated blood pressure and also reported "stabbing back pain".  EMT was called and assessed her.  She did not go to the hospital.
Severe extremity edema, hives with pruritus.  Mild shortness of breath. None of these events occurred with first dose. Have taken Benadryl 25mg every 6 hours. Still persistant.
Pt had redness, hives, and itchness around site of injection. Hives travelled down to elbow. Pt went to Urgent care, and swelling went down the next day
2 days after I received the 2nd shot I got very sick with body aches and fever.  4 days after the vaccine I woke up at 1:00 A.M. with chest pain.  This happened every night for 3 days and the pain got worse every night.  After the 3rd night I decided to go to the urgent care to have an EKG done.  They did and EKG and said I was having a Heart Attack and rushed me to the ER.  At the ER they ran blood tests and X-Ray of my heart.  The doctor came back and said that I had Pericarditis and gave me a 10 day prescription for Indomethacin.  The chest pains have gone away but I do have a slight pressure in my chest every few weeks.
4 days after the first Moderna shot I woke up in the middle of the night with shingles. Shot in left arm, shingles on right thigh.
After injection, the patient claims to have had arm soreness. The day after the injection, and continuing through 2 weeks post-injection, patient complains of continuous body aches, chills, and headache. The patient was advised to report to her PCP and was provided with GSK's 800-phone number to contact them, report her s/s, and ask about recommendations on their end.
Apps 15 hours after- 102 fever, fever of 100; extreme chills; 26 hours after, sever body aches; especially though arms; neck ache; ache kidney area; fatigue, no fever but still tired; This is a spontaneous report from a non-contactable consumer or other non-HCP. A 46-years-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE Formulation: Solution for injection, Lot number: EN5318), dose 2 via an unspecified route of administration in left arm on 10Feb2021 at 07:15 (at the age 46 years) as 2nd dose, single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. Patient had no allergies to medications, food, or other products. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received first dose of BNT162B2 on an unspecified date for COVID-19 immunization. Prior to vaccination, the patient was not diagnosed with COVID-19. On 10Feb2021 at 10:00, (15 hours after) patient experienced 102 fever and extreme chills. On an unspecified date in Feb2021, (26 hours after), patient experienced severe body aches especially though arms, neck, and kidney area, fatigue and fever of 100. On an unspecified date in Feb2021 (48 hours after), patient experienced slightly achy, no fever but still tired. The treatment was not received for the adverse events. The patient has been tested for COVID-19 (SARS-CoV-2 test): negative on 11Feb2021. The outcome of the events was recovering.  No follow-up attempts are possible. No further information is expected.